Huntington's

The latest sourced reporting on Huntington's from Dementias Today: dated, and plain about what the evidence does and does not show.

The package that has to find the basement

An open-access review in Advanced Healthcare Materials catalogues the nanoparticles engineered to carry drugs all the way to failing mitochondria in neurodegeneration, and states on its own first pages that none has been approved for anyone.

PAHO Finds Long-Term Care Policy Has Outpaced Financing Across the Americas

A regional midterm review of the UN Decade of Healthy Aging finds that the share of countries in the Americas with a national long-term-care policy jumped from 61 percent to 88 percent since 2020, but the money and services to make those policies real have not kept pace, with direct consequences for how dementia care gets funded and staffed.

When the person you care for does not know they are ill

Amsterdam UMC researchers interviewed 14 pairs, the person with the diagnosis and the family member caring for them, about impaired awareness in dementia, Huntington's disease and Korsakoff's syndrome. Both sides were in the room, and they described two different lives.

Eleven Irish carers, and the risk nobody put on the form

A small qualitative study from Beaumont and Limerick asked family carers of people with Huntington's disease what the job feels like. The genetic dread they described was real, but it pointed at their children, not at themselves.

Editing Msh3 in mouse brain slows Huntington's CAG expansion, and earlier is better

A preprint posted to bioRxiv on June 8, 2026 by a Massachusetts General Hospital group reports that knocking out the mismatch repair gene Msh3 in the striatum of Huntington's model mice at three different ages slowed further CAG repeat expansion and reduced molecular and histological signs of disease, with the largest effect when editing was done earliest. The work is in mice, and it has not been peer reviewed.

uniQure to file for US approval of Huntington's gene therapy on three-year data

The FDA has told the company that the roughly three-year analysis of its phase 1/2 striatal gene therapy AMT-130, which reported 75 percent slowing on a composite rating scale in 12 high-dose patients against an external control, can be the primary basis for an accelerated-approval application. The filing is planned for this quarter, and a confirmatory trial would still be required.